Using SGLT2 inhibitors to improve gout care
Official title: SGLT2i As Novel Gout Care (SAVE-Care): A Randomized Controlled Trial
Funded at Massachusetts General Hospital · NIH-11047879 · Data updated 2026-11-12
This study is looking at whether a type of medication called SGLT2 inhibitors can help people with gout feel better and reduce their risk of heart problems, and it’s for adults who experience gout flare-ups.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | June 18, 2025 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $228,218 |
| NIH project number | 1R61AR084188-01A1 |
| Project ID | NIH-11047879 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who have been diagnosed with gout and may also have cardiovascular or kidney comorbidities.
✕Less likely to help
Patients who do not have gout or those with contraindications to SGLT2 inhibitors may not benefit from this research.
What this research studies
This research investigates the potential of sodium-glucose cotransporter-2 inhibitors (SGLT2i) to improve the management of gout, a common inflammatory arthritis affecting millions of adults. The study aims to evaluate how these medications can reduce gout flares and associated cardiovascular risks, which are significant concerns for patients with this condition. By conducting a randomized controlled trial, the research will compare the effects of SGLT2i on gout symptoms and overall health outcomes against standard treatments. Patients participating in this trial will be closely monitored to assess the effectiveness of this novel approach.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for gout patients, reducing flare-ups and associated cardiovascular risks.
How similar studies have gone: Previous studies have shown that SGLT2 inhibitors can provide cardiovascular and kidney benefits, suggesting a promising avenue for gout management.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Choi, Hyon K — Massachusetts General Hospital
- Study coordinator: Choi, Hyon K
Related research
Other NIH-funded projects on the same topics.
-
Treat-to-Target Urate in Gout: A New Approach for Better Pain and Health
A large clinical trial tests whether aiming for a specific uric acid level in gout patients improves symptoms and health outcomes compared with avoiding symptoms.
-
SGLT2 inhibitors for gout care in adults with diabetes
A randomized trial is testing whether an SGLT2 inhibitor can help reduce gout flares and improve heart and kidney health in adults with type 2 diabetes.
-
Targeting low blood uric acid versus treating gout flares for adults with gout
This compares keeping blood uric acid below a set level versus treating gout flares only, for adults living with gout.
-
Comparing treatment strategies for managing gout symptoms and serum urate levels
This study is looking at two ways to help people with gout: one that tries to lower uric acid levels in the blood and another that focuses on easing pain and other symptoms, so if you have gout, you can help us find out which method works better for your health!
-
Cognitive behavioral therapy and trazodone for insomnia phenotypes with high blood pressure
A clinical study tests how CBT-I and the sleep drug trazodone work for adults with insomnia and high blood pressure, focusing on a specific sleep duration pattern.
-
Shorter antifungal treatment for kids with candidemia
A multi-center pediatric trial tests whether a shorter, 7 extra days of antifungal therapy after an initial 7 days is just as good as the standard 14-day approach for kids with candidemia who are improving on echinocandin therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.